AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Net Receivables · Q3 FY2025 · quarter ended Sep 2025
Net receivables of €0 in Q3 FY2025
Q3 FY2025 net receivables was €0.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
Currency unavailable · from the balance sheet
No Net Receivables data reported for this period type.
Net Receivables vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Net receivables amounts to 0.0% of total assets for AGMB, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $25.75M USD | +44.0% | +187.9% | 7.8% | |
| Mar 2026 | $4.81M USD | +1825.6% | +125.7% | 2.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $3.86M USD | -50.9% | +60.9% | 0.7% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €0 EUR | — | — | 0.0% |
| Mar 2026 | $0 USD | -100.0% | -70.3% | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -3.5% | +93.3% | 1.6% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.